The approval of the first oncolytic viral therapy, Imlygic, in the United States and EU5 in 2015 and 2016, respectively, marks a significant milestone for cancer vaccines and viral therapies,…
With a growing population and an enormous clinical need for improved treatments, the market for Alzheimer’s disease (AD) pharmacotherapies represents a massive commercial opportunity that…
This detailed, expanded analysis explores key access and reimbursement topics in the rare disease space in the United States, such as the approaches managed care organizations take to control both…
Abstract Introduction: With a growing number of biosimilars in development and the launch of the first FDA-approved products in 2015, biosimilars are set to gain an increasing share of the…
Neuropathic pain (NP) is a prominent form of pain associated with a variety of diseases and conditions, including cancer, diabetes, herpes zoster, chronic back pain, and multiple sclerosis. A…
Atopic dermatitis (AD), also known as (atopic) eczema, is a chronic, relapsing inflammatory skin disease marked by severe pruritus and skin irritation which can have a strong negative impact on…
In recent years, biosimilars of epoetin alfa and filgrastim have been approved and launched in major markets. Uptake of these products among oncologists is increasing, driven by payers and…
For the estimated 9.5 million people in the United States who are living with a history of diagnosed psoriasis, there are multiple prescription therapies that are available for treating the mild to…
Overactive bladder (OAB) is a common symptom complex characterized by urinary urgency, incontinence, frequency, and nocturia, which occur in the absence of pathologic or metabolic factors that…
Gaining physician confidence is critical to securing a meaningful position in developed markets; therefore, understanding their concerns about biosimilar products should be an important part of…
This quarterly report series covers the management of dialysis and mid- to late-stage chronic kidney disease (CKD) patients from the perspective of nephrologists. Emphasis is on anemia management (…
Psoriasis is a chronic inflammatory skin disorder that, although non-life-threatening, can have a major impact on patients’ quality of life depending on its severity and location on the body. The…
Psoriasis is a chronic inflammatory skin disorder that is managed with systemic therapies for moderate to severe patients who fail first-line topical therapies and/or phototherapy. Dermatologists…
European oncologists have had high exposure to biosimilars compared with other European specialists owing to the availability of epoetin alfa and filgrastim biosimilars. Although no biosimilars are…
Renal anemia and hyperphosphatemia, or elevated serum phosphorous, are two primary complications of chronic kidney disease (CKD) that are treated with erythropoiesis-stimulating agents (ESAs) and…